| Date | Title | Description |
| 02.09.2026 | Psilocybin, LSD Hallucination Fingerprint Identified: Cell Test Bypasses Animal Screens | By Jackie Manning
Published: Sep 02 2026, 9:40 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 11.08.2026 | Institute for Integrative Therapies Selected as Clinical Trial Site for COMPASS Pathways’ Psilocybin Treatment for PTSD | Minnesota research center expands its psychedelic medicine research program into post-traumatic stress disorder
EDEN PRAIRIE, MN, UNITED STATES, August 11, 2026 /EINPresswire.com/ -- The Institute for Integrative Therapies (IIT) announced t... |
| 05.08.2026 | Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights | Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today reported the second quarter and first half 2026 financial results and business highlights... |
| 29.07.2026 | Compass Pathways to Announce Second Quarter and First Half 2026 Financial Results on August 5, 2026 | Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that it will release financial results for the second quarter and first half en... |
| 24.07.2026 | Pharmaceutical Frontier: Psychedelics Rise, GLP-1s Diversify, Global Innovation Thrives | The pharmaceutical industry undergoes rapid transformation. Big Pharma embraces psychedelic drugs, acquiring key innovators to treat diverse mental health conditions. This signals a new era for depression, PTSD, and anxiety therapies. Concu... |
| 19.07.2026 | The market for psychedelic drugs to treat mental health conditions gets a big buy signal | To learn more about the CNBC CFO Council, visit cnbccouncils.com/cfo
Thursday’s announcement that Eli Lilly will acquire AtaiBeckley, a clinical-stage maker of psychedelic drugs, for up to $3.8 billion indicates Big Pharma’s increasing embr... |
| 14.07.2026 | FDA Finalizes Psychedelic Trial Rules: Unblinding Problem Gets Official Answer | By Philip Nickell
Published: Jul 14 2026, 2:21 PM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 31.05.2026 | Why Trump reversed course to fast-track psychedelic drugs for mental healthcare | President Donald Trump aims to fast-track research into psychedelic therapy for conditions like post traumatic stress disorder and depression in a break from his first administration policy.
Advocates see the move as a major step forward, b... |
| 13.05.2026 | Compass Pathways Announces First Quarter 2026 Financial Results and Business Highlights | Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported first quarter 2026 financial results and business highlights.
“With regulato... |
| 06.05.2026 | Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026 | Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter ended March 31... |
| 21.04.2026 | 5 Things to Know
Apple’s next CEO, Warsh’s confirmation hearing, the psychedelic stock surge and more in Morning Squawk | This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox.
Happy Tuesday. President Donald Trump will join CNBC’s “Squawk Box” for a live interview at 8:30 a.m. ET this morning. Watch live on CNBC or ... |
| 20.04.2026 | Three psychedelics stocks surge after Trump executive order. Oppenheimer sees more upside ahead | - |
| 29.03.2026 | Psychedelic therapies are becoming mainstream. Deutsche Bank thinks this drug developer could triple | - |
| 24.03.2026 | Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights | Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported the fourth quarter and full-year 2025 financial results and business highlig... |
| 23.02.2026 | Compass Pathways Announces Pricing of $150 Million Public Offering | Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a pu... |
| 04.11.2025 | Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months | Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2025 and provided an update on r... |
| 22.10.2024 | Global Wellness Summit Unveils Packed 3-Day Agenda for Sold-Out Conference Taking Place in St Andrews, Scotland - November 4-7 | Global Wellness Summit Unveils Packed 3-Day Agenda for Sold-Out Conference
High-profile wellness leaders, innovators and experts will explore the powerful shifts and transformative trends underway in the wellness industry, centered around t... |
| 15.08.2024 | Greenbrook TMS: Navigating Legal Waters and Financial Challenges | Greenbrook TMS Inc. is in the spotlight, facing both legal and financial hurdles. The company recently announced a settlement with Benjamin Klein, a significant player in its operational landscape. This settlement, valued at $800,000, inclu... |
| 13.08.2024 | GREENBROOK TMS REPORTS SECOND QUARTER OPERATIONAL AND FINANCIAL RESULTS | TORONTO, Aug. 13, 2024 /PRNewswire/ - Greenbrook TMS Inc. (OTCQB: GBNHF) ("Greenbrook" or the "Company") today announced its second quarter 2024 ("Q2 2024") operational and financial results. All values in this... |
| 03.06.2024 | Landmark review spotlights challenge of judging psychedelic therapies | figcaption>span]:font-sans">
The challenges of mainstreaming psychedelic therapies for conditions like PTSD, anxiety and major depression will be brought home this week when federal drug advisers scrutinize what could be the firs... |
| 13.09.2023 | Norrsken Foundation launches psychedelic science initiative for mental health | Norrsken Foundation has today announced the launch of Norrsken Mind: Psychedelic Science Initiative, a foundation focused on the treatment of mental health through psychedelic substances. Norrsken Mind has raised over €3 million and says th... |
| 18.08.2023 | COMPASS Pathways to advance psilocybin therapy with up to $285M in new financing | COMPASS Pathways, a London-based, Nasdaq-listed company working in the field of mental health treatment via psilocybin therapy, is poised to raise up to $285 million in a private placement financing round. The transaction
The transaction is... |
| 17.08.2023 | UK-based COMPASS Pathways secures €261.8M to advance mental health solutions | Read this article in:
London-based COMPASS Pathways, a biotech company that accelerates patient access to evidence-based innovation in mental health, announced on Wednesday, August 16, that it has secured $285M (nearly €261.89M) in private ... |
| 16.08.2023 | COMPASS Pathways Announces Up to $285 Million Private Placement Financing | - |
| 05.07.2023 | COMPASS Pathways Secures Term Loan Facility for Up to $50 Million from Hercules Capital | - |
| 02.03.2023 | COMPASS Pathways to participate in upcoming Cowen 43rd Annual Health Care Conference, Oppenheimer 33rd Annual Healthcare Conference, and Loop Capital Investor Conference | LONDON, March 02, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc CMPS, a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in t... |
| 17.02.2023 | These investor-backed mental health startups are healing our brains | At least 1 in 5 people will experience mental illness at any time.
Yet for many, treatment is prohibitive due to long-waiting lists for mental health professionals, hospital bed shortages, and medication that comes with adverse side effects... |
| 15.02.2023 | How a family's struggle to help their son gave rise to controversial $400 million psychedelics giant Compass Pathways | This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Redeem now
Allan Malievsky had to take a break.
A sophomore at George Washington University, Malievsky was struggling with depression, anxi... |
| 09.11.2022 | Compass Pathways' new CEO says data from his firm's upcoming clinical trial could finally persuade Big Pharma to jump into the psychedelics industry | Kabir Nath, the CEO of Compass Pathways. Compass Pathways This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Redeem now
Compass Pathways is set to start its biggest clinical trial yet by the... |
| 24.08.2022 | Psilocybin: A Promising New Treatment for Depression | Psilocybin is being studied as a potential treatment for a number of physical and mental health concerns, but treating depression is its most promising use yet. VANCOUVER, BRITISH COLUMBIA, CANADA, August 24, 2022 /EINPresswire.com/ -- Psyc... |
| 08.03.2022 | Pep talk: Fever founder Pep Gómez tells about his years in Silicon Valley, handling rejection, and what he's betting on next | Pep Gómez got an early start in entrepreneurship.
Having started his first company at age 14, as soon as he left school the native of Castellón headed off to do an internship in Silicon Valley, where he founded live-entertainment discovery ... |
| 10.02.2022 | Celebrating women and girls in science: Rana's story | What inspired you to become a scientist?
As a child, I was very curious. Often the people around me did not have the answers to my questions, so I had to go looking myself. Tell us about your studies. Where has your career in science taken ... |
| 18.01.2022 | Study Finds 65% Of Americans With Mental Health Conditions Want Access To Psychedelics | The Mexican magic mushroom is a psilocybe cubensis, a specie of psychedelic mushroom whose main ... [+] active elements are psilocybin and psilocin - Mexican Psilocybe Cubensis. An adult mushroom raining spores. red and blue color. horizont... |
| 02.01.2022 | The 6 most mind-blowing human health discoveries of 2021 | COVID-19 research was just the tip of the iceberg for 2021 discoveries.
Getty Images
There were many important scientific discoveries unrelated to Covid-19 this year.
Scientists have studied and developed new treatments for everything from ... |
| 27.12.2021 | The 6 most mind-blowing human health discoveries of 2021 | COVID-19 research was just the tip of the iceberg for 2021 discoveries. Getty Images
There were many important scientific discoveries unrelated to COVID-19 this year.
Scientists have studied and developed new treatments for everything from ... |
| 29.11.2021 | Atai Life Sciences Increases its Ownership Position in COMPASS Pathways | Demonstrates atai’s confidence in COMPASS’ Phase 2b data and its potential for patients with treatment-resistant depression
Reinforces COMPASS as highly complementary to atai’s diversified approach to innovation in mental health
NEW YORK, N... |
| 29.11.2021 | UK impact startups raise €2.36B to solve the world’s biggest challenge: Know more here | As technology becomes all important in solving global problems such as climate change, escalating health risks, and food insecurity, UK impact tech startups – companies founded to build solutions to the UN Sustainable Development Goals – ha... |
| 09.11.2021 | COMPASS Pathways plc announces financial results and business highlights for the third quarter 2021 | Highlights:
Positive topline results from phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression; rapid and sustained response for patients receiving a single 25 mg dose of COMP360 psilocybin with psychological suppor... |
| 09.11.2021 | Largest psilocybin trial finds the psychedelic is effective in treating serious depression | Eagerly awaited results of the largest-ever study of psilocybin were announced Tuesday, with Compass Pathways revealing the psychedelic drug was highly efficacious as a therapy for treatment-resistant depression. Still, the company’s stock ... |
| 09.11.2021 | Compass Pathways' Phase IIb psilocybin trial shows reduced depression symptoms | UK biotech Compass Pathways revealed this morning that they reached the primary endpoint in a Phase IIb clinical trial of psilocybin therapy.
In the randomized, controlled and double-blind trial, investigators looked ... |
| 09.11.2021 | COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression | Largest randomised, controlled, double-blind psilocybin therapy study ever completed
shows rapid and sustained response for patients receiving a single dose of COMP360 psilocybin
with psychological support
COMPASS management team to host an... |
| 22.10.2021 | COMPASS Pathways : Our wellbeing programme at COMPASS | At COMPASS Pathways, our vision is a world of mental wellbeing, and that starts with making sure that everyone who works here feels supported and able to access help. We talk to Anne Benedict, our Chief People Officer, about our approach to... |
| 10.09.2021 | Seattle-area psychedelics startup CaaMTech raises $22M to advance to human testing | CaaMTech aims to take the uncertainty out of psychedelics like magic mushrooms and provide defined formulations. (BigStock Photo)
CaaMTech, a Seattle-area startup developing new psychedelic agents, has raised $22 million in funding, the com... |
| 11.08.2021 | COMPASS Pathways : announces financial results and business highlights for the second quarter 2021 | Highlights:
Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021
Partnership being developed with leading UK institutions to accelerate psychedelic r... |
| 30.07.2021 | Tilray’s war chest | Employees tend to medical cannabis plants at Pharmocann, an Israeli medical cannabis company in northern Israel. Amir Cohen/Reuters
Welcome to Insider Cannabis, our weekly newsletter where we’re bringing you an inside look at the deals, tre... |
| 30.07.2021 | COMPASS Pathways : Learning from Plastic Free July | Each year, about 400 million tonnes of plastic is produced, and half of that is single-use, such as plastic bags, drinks bottles and crisp packets. Eight million tonnes of plastic waste ends up in our oceans annually, polluting the seas and... |
| 23.07.2021 | Amazon lobbying on legalization | Welcome to Insider Cannabis. AP Photo/Richard Vogel
Welcome to Insider Cannabis, our weekly newsletter where we’re bringing you an inside look at the deals, trends, and personalities driving the multibillion-dollar global cannabis boom.
Sig... |
| 21.07.2021 | See the pitch deck that Compass Pathways used to raise $80 million and fuel its rise into one of the world's biggest psychedelics companies | Psilocybin mushrooms on a mossy log jackfoto/iStock/Getty Images Plus This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Compass Pathways is one of the biggest psychedelics companies in the ... |
| 24.06.2021 | COMPASS Pathways Becomes Founding Supporter Of The British Neuroscience Association’s Inaugural Scholars Programme | Programme aims to support students from under-represented ethnic groups
COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has become a Founding Supporte... |
| 03.06.2021 | Psychedelic healthcare fund Neo Kuma sees early success amid sector growth | The UK’s first investment fund dedicated solely to psychedelic healthcare, Neo Kuma is reporting that a number of its early investments are returning yields between 180% and 680%, with three of the seven companies in its portfolio planning ... |
| 24.05.2021 | COMPASS PATHWAYS PLC
COMPASS Pathways : THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION (Form 6-K) | THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION.
If you are in any doubt as to the action to be taken, please seek your own financial advice from your stockbroker, solicitor, accountant or other appropriately authorised ind... |
| 14.04.2021 | A landmark study shows the main compound in magic mushrooms could rival a leading depression drug | Psilocybin in pill form NYU Imperial College London scientists just published a report on how psychedelics could treat depression. The study pits psilocybin, the active compound in magic mushrooms, against the depression drug escitalopram. ... |
| 15.11.2020 | Как инвестировать в компанию по изучению галлюциногенных грибов? | 12 12 комментариев
916 просмотров
В 2014 году моя жена проснулась в холодном поту посреди ночи. Она пожаловалась на сердце и одышку. Через пару дней приступ повторился. Физически она была здорова. После массы анализов ей поставили диагноз «... |
| 29.10.2020 | Пятеро россиян вошли в топ-100 самых богатых британских предпринимателей по версии The Telegraph | Состояние Сторонского издание оценило в £1,06 млрд ($2 млрд). Он единственный миллиардер в списке.
На 22-й строчке рейтинга — основательница медицинского стартапа Compass Pathways Екатерина Малевская с состоянием £61 млн ($79,3 млн). Компан... |
| 18.09.2020 | News briefing: Company developing 'magic mushroom' treatment hits Nasdaq; SpringWorks enters sponsored research agreement with Fred Hutch | Compass Pathways seeks to raise $127.5 million in an upsized IPO, by offering 7,500,000 shares priced at $17 apiece. The London-based company had initially filed for a $100 million IPO, according to its F-1 filing.
The compa... |
| 11.08.2020 | От медитаций до лекарств от депрессии: в 2020 году стартапы для ментального здоровья стали чаще привлекать инвестиции Статьи редакции... | Только во втором квартале 2020 года, во время пандемии и ограничительных мер, инвесторы поддержали 57 проектов.
13 13 комментариев
3515 просмотров
6 августа американский сервис для психотерапии Ginger получил инвестиции на $50 млн от частно... |
| 06.05.2020 | Psychedelic Drugs Can Improve Quality Of Life - And Death - For Older Adults | Getty |
| 30.04.2020 | Oregon psychedelic startup tests nasal spray for PTSD, depression as legislative momentum builds | Mike Arnold, the founder of Silo Wellness, on a trip to Jamaica. (Photo courtesy Mike Arnold)
If you want to know just how quickly public sentiment around psychedelics is changing, consider this: Gwyneth Paltrow sent her staffers to psilocy... |
| 27.04.2020 | Compass Pathways secures $80 million Series B to boost depression clinical trial | (Editor’s Note: this is an article from Crunchbase News by Christine Hall, syndicated with permission as part of a new content and data partnership.)
Compass Pathways’ work on treatment-resistant depression received a big backing from inves... |
| 27.04.2020 | Compass Pathways Closes $80M Series B Funding | Compass Pathways, a London, UK-based mental health care company, completed an $80m Series B funding round.
Backers included existing investor ATAI Life Sciences and new investor the McQuade Center for Strategic Research and Development (a m... |
| 27.04.2020 | Compass Pathways Secures $80M Series B to Boost Depression Clinical Trial | 32 Shares Email Facebook Twitter LinkedIn
Compass Pathways’ work on treatment-resistant depression received a big backing from investors.
Subscribe to the Crunchbase Daily
The London-based mental health care company closed a funding infusio... |
| 07.01.2020 | Transforming psychedelics into mainstream medicines | Research on psychedelics, which have been profoundly stigmatized, highly restricted, and tragically undeveloped for more than half a century, is stirring back to life and rekindling scientific, medical, and cultural interest in these compou... |
| 22.08.2018 | Magic mushrooms might treat depression? Peter Thiel-backed Compass gets FDA OK to launch Phase IIb trials | For years now, psychedelic scientists have been telling us that tripping on magic mushrooms might “reboot” the brain, clearing out negative thought networks that might contribute to depression. Now, it looks like the FDA is ... |
| - | Psychedelic biotech Eleusis enters SPAC deal to take depression drug to the clinic | When it comes to drug formulations, pills are generally preferred to injections and infusions. They’re more convenient for patients since dosing doesn’t require a visit to a clinical site. But in depression, pill versions of the psychedelic... |
| - | Psychedelics aren't going to upend mental healthcare anytime soon. Here's how long it will be until the emerging field turns research into reality. | Companies are racing to turn psychedelics into approved medical treatments. IStock; Vicky Leta This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Insider is tracking the most important psych... |
| - | Wealthy donors are fueling a psychedelics renaissance as universities vie for funding to study 'magic mushrooms' and MDMA | This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Universities are establishing psychedelics centers to study compounds like psilocybin and MDMA. Cash from wealthy donors and promising earl... |
| - | ‘It’s not medical’: Oregon wrestles with how to offer psychedelics outside the health care system | PORTLAND, Ore. — Visitors to the fabric store, kitty-corner to a Whole Foods, are greeted by a sign on the glass front door. Outlined in red, it says: “NO drugs, NO money kept in this building.” Not for much longer.
Come early next year, if... |
| - | COMPASS Pathways | “COMPASS is a mental health care company dedicated to accelerating patient access and experience to evidence-based innovation in mental health care.” |
| - | Pep talk: Fever founder Pep Gómez tells about his years in Silicon Valley, handling rejection, and what he's betting on next | Pep Gómez got an early start in entrepreneurship.
Having started his first company at age 14, as soon as he left school the native of Castellón headed off to do an internship in Silicon Valley, where he founded live-entertainment discovery ... |
| - | Amazon lobbying on legalization | Welcome to Insider Cannabis. AP Photo/Richard Vogel
Welcome to Insider Cannabis, our weekly newsletter where we're bringing you an inside look at the deals, trends, and personalities driving the multibillion-dollar global cannabis boom.
Sig... |
| - | Psychedelic healthcare fund Neo Kuma sees early success amid sector growth | The UK’s first investment fund dedicated solely to psychedelic healthcare, Neo Kuma is reporting that a number of its early investments are returning yields between 180% and 680%, with three of the seven companies in its portfolio planning ... |
